At the 2026 ESC Congress in Munich, CSPC Pharmaceutical Group presented positive Phase II results for SYH2053, a novel PCSK9-targeting siRNA therapy for primary hypercholesterolemia and mixed dyslipidemia. The randomized, double-blind, controlled trial enrolled 156 Chinese patients across five groups. At Day 180, SYH2053 reduced placebo-adjusted LDL-C by 46.6%, 52.9%, and 46.4% at 150, 300, and 600 mg, respectively (all p<0.0001), with rapid and sustained reductions in LDL-C and PCSK9. The 300 mg group showed numerically greater LDL-C and PCSK9 reductions than 300 mg inclisiran with background therapy. SYH2053 had a favorable safety profile, with lower rates of liver enzyme elevation than inclisiran. Three Phase III trials are underway to further validate its efficacy and safety.

Dizal Pharmaceutical listed on Shanghai's STAR Market in 2021, raising about RMB 2.1 billion, and filed an H-share application with the Hong Kong Stock Exchange in August 2026, pursuing an A+H dual listing. Formerly AstraZeneca's early-stage drug discovery unit in Asia, it was spun off in 2017 with preclinical assets and funding from AstraZeneca, led by CEO Zhang Xiaolin, PhD. At its STAR listing, only two candidates were in late-stage development; in August 2023, Zegfrovy (sunvozertinib) became China's first innovative drug for EGFR exon 20 insertion-mutant NSCLC, lifting H1 2026 revenue to RMB 523 million. After filing its Hong Kong prospectus, Dizal signed a record-breaking license agreement with AstraZeneca effective August 31, securing a USD 600 million upfront (about RMB 4 billion) and other payments. The company is not yet overall profitable, with multiple pipelines awaiting clinical validation.

Kossel Medical Technology (Suzhou) Co., Ltd. has raised RMB 400 million in Series C financing, co-led by Shenzhen Capital Group and Kinghall Ventures, with participation from Frontier Investment and Chuangjing Capital, plus continued investment from existing shareholders. Xiqiao Capital acted as financial advisor. The proceeds will support capacity expansion, global registration, and R&D in peripheral, coronary, and electrophysiology interventions. Founded in 2013, Kossel is a national-level “Little Giant” enterprise with over 300 patents and nearly 100 global regulatory approvals, covering peripheral, coronary, electrophysiology, and biomaterials. Recent acquisitions of Baiquantong Medical and XinZhi Medical, along with partnerships with InnoMed, Silvan Medical, Abbott, and Medtronic, have strengthened its ecosystem. With manufacturing centers in Europe and Southeast Asia and operations in over 20 countries, Kossel is advancing its “Local Base, Global Reach” strategy.

GensKey’s self-developed mNGS kit has received a Class III medical device registration certificate from China’s National Medical Products Administration (NMPA), marking China’s first Class III registration for pathogen metagenomic testing and the first mNGS infectious pathogen diagnostic kit approved by a national regulator worldwide. The U.S. FDA has yet to approve any mNGS diagnostic kit, while the EU has not completed approval of any broad-spectrum infectious pathogen mNGS sequencing kit. China’s lead reflects strong clinical demand and rapid technological iteration. With mNGS and tNGS still at low penetration but high growth, clinical needs are accelerating standardization, regulatory approval and reimbursement. As a key tool for severe and complex infections, mNGS has historically relied on centralized laboratories with limited standardization. The new Class III approval could reshape the market and unlock a billion-yuan incremental opportunity.

Inspired by Avatar, Tianjin University graduate Zhang Xingzhi became convinced that brain-computer interfaces (BCI) would reach an industrialization tipping point. Over a decade, he progressed from human-computer interaction research to an executive role at a listed company. In 2025, amid policy and technological breakthroughs, he resigned to found WABO Technology. The company completed three financing rounds within three months. Rather than focusing on medical applications, WABO Technology centers on the “Human Neural Intent Model,” integrating proprietary hardware with software to collect neural signals and build a large EEG model. Zhang believes BCI will have a “GPT moment,” driven by massive real-world neural data. By end-2025, he had built a core team in Chengdu and adopted a lightweight, AI-native model.

Suzhou Ribo Life Science Co., Ltd. presented promising Phase 1 clinical data for RBD5044, an siRNA therapeutic targeting ApoC3, at the ESC Congress 2026. A single dose of RBD5044 suppressed ApoC3 levels by up to 84% and reduced triglycerides by up to 70%, with durable effects sustained over six months. The drug demonstrated good safety and tolerability with no liver enzyme elevations. RBD5044 is currently advancing into Phase 2 clinical trials in China and Sweden for the treatment of hypertriglyceridemia.

China's Center for Drug Evaluation (CDE) has signaled that YL202, an injectable HER3-targeted antibody-drug conjugate (ADC) developed by MediLink Therapeutics, is being considered for Breakthrough Therapy Designation for the treatment of previously treated, unresectable locally advanced, recurrent or metastatic melanoma. If approved, YL202 would become the first HER3 ADC to receive breakthrough therapy status in China. Currently in Phase III clinical development, YL202 is built on MediLink's proprietary TMALIN platform. The potential designation underscores the significant unmet medical need in advanced melanoma and highlights the growing competitiveness of Chinese biotech in the rapidly expanding ADC space, where no HER3 ADC has been approved globally to date. MediLink has also secured a major licensing deal with BioNTech worth up to $1 billion, reflecting strong global interest in Chinese-developed oncology therapies.

In August, China's National Medical Products Administration (NMPA) approved a wave of homegrown Class 1 anticancer therapies, marking a banner year for domestic pharmaceutical innovation. Key approvals include Hutchison Meditech's fruquintinib for FGFR2-altered intrahepatic cholangiocarcinoma, TYK Medicines' deuceronib for EGFR-mutant NSCLC with brain metastases, and Chongqing Genrix's weilaituomab for heavily pretreated multiple myeloma. These approvals signal a strategic shift among Chinese drugmakers from volume-driven development toward clinically differentiated, globally competitive therapies addressing significant unmet medical needs.

BCIs have long faced neural decoding latency, limiting patients’ sense of “embodiment” and prosthetic integration. Recently, the Shanghai Institute of Microsystem and Information Technology of the Chinese Academy of Sciences and QBOSON achieved microsecond-level neural decoding on a 1,000-qubit quantum computer, offering a potential solution to computational bottlenecks. Following the breakthrough, China’s first BCI-specific fund, the “Heying Brain-Computer Interface Fund,” partnered with QBOSON. The two sides plan to leverage quantum computing to process massive noisy neural signals and accelerate deep-brain intention decoding via cloud computing. Within three to five years, they aim to achieve hardware-accelerated decoding for language and motor applications, potentially overcoming BCI latency and advancing the technology toward becoming an extension of the human body.

Haofeng Medical, China's first full-chain CDMO platform for interventional medical devices, has secured nearly RMB 100 million in strategic financing led by a fund under Taizhou China Medical City Huayin Jintou. The funding will accelerate capacity expansion, business development, and global footprint, reinforcing its integrated CDMO advantage across four core platforms: Equipment, Components, Materials, and Energy. Headquartered in Shanghai’s Lingang New Area with manufacturing bases in Taizhou and Zhuhai, Haofeng serves over 60 domestic and international clients across nine clinical domains, delivering end-to-end contract development and manufacturing services without competing as a brand owner. The company, which holds over 350 patents and operates a 30,000+ sqm facility network, is advancing its AI-driven digital factory in Taizhou to become a global benchmark in lean, transparent, and intelligent interventional device manufacturing.

BD deals between US and European pharma are growing more complex and volatile, signaling new shifts across the innovative drug industry. "BD Deep Dive" focuses on how IIT clinical research is reshaping FDA approvals, capital markets, and cross-border collaboration models. Industry insiders said a US rare-disease company is preparing to partner with a Chinese drugmaker on an siRNA IIT study, using Chinese data to accelerate FDA approval and cut early-stage clinical costs. Beacon Capital's founder noted that many overseas companies frequently sought IIT resource connections in China over the past six months, covering small nucleic acids and gene therapy. Although the new Regulation No. 818 brings uncertainty, IIT cases unlocking M&A and capital-market value still attract global biotechs. Overseas companies hope to use China's vast patient pools and efficient clinical system as a "fast track" to the FDA, compressing time and capital costs.

Inspired by Avatar, Tianjin University graduate Zhang Xingzhi became convinced that brain-computer interfaces (BCI) would reach an industrialization tipping point. Over a decade, he progressed from human-computer interaction research to an executive role at a listed company. In 2025, amid policy and technological breakthroughs, he resigned to found WABO Technology. The company completed three financing rounds within three months. Rather than focusing on medical applications, WABO Technology centers on the “Human Neural Intent Model,” integrating proprietary hardware with software to collect neural signals and build a large EEG model. Zhang believes BCI will have a “GPT moment,” driven by massive real-world neural data. By end-2025, he had built a core team in Chengdu and adopted a lightweight, AI-native model.

In collaboration with Central South University, Tencent's AI for Life Sciences laboratory has built a new AI framework, UniPert-G2CP, with its paper accepted by Cell. The model integrates multimodal molecular perturbation factor representations, enabling transfer learning from genetic to chemical perturbation phenotypes, connecting genetic and chemical screening for more accurate perturbation prediction, mechanism discovery, and efficient computer-assisted drug screening. Its breakthrough: answering why the same compound responds differently across genetic and cellular contexts. Previous AI achievements in drug development shared a blind spot — ignoring downstream effects after compounds enter real cells, making results irreproducible and costly for pharma. UniPert-G2CP, a two-stage deep learning framework, predicts phenotypic responses to compounds in specific cellular contexts from gene-level perturbation information, offering a solution to this dilemma.

Over the past six months, more than $8 billion has flowed into the oral cyclic peptide sector through financing and BD deals, as Big Pharma and leading investors compete for platforms and pipelines. Recent FDA approvals of MSD’s Enlicitide and J&J’s Icotrokinra have validated the modality, but most assets remain preclinical or in early clinical development, with low oral bioavailability still a key technical hurdle. AI-driven platforms from Unnatural Products, Syneron Bio, and Pinnacle Medicines are attracting substantial capital, signaling a shift toward platform capabilities that can iteratively address these challenges. While validated extracellular targets offer near-term commercial certainty, the greater long-term potential lies in drugging intracellular targets inaccessible to small molecules or antibodies. Given the high scientific and development risks, platform resilience and a staged target strategy will be critical to success.

On August 25, Shanghai Pharmaceuticals announced its subsidiary SPH Holding will publicly list for transfer a 51% stake in Shanghai Shangyao Xinte Dongan Pharmacy at a minimum price of RMB 178.5 million, exiting control of the pharmacy upon completion. The move follows a year of intensive restructuring of retail pharmacy assets nationwide, as state-owned pharmaceutical platforms accelerate divestment of non-core assets. Founded in September 2023, the pharmacy has shown strong profitability in its three years: 2025 revenue of RMB 384 million, net profit of RMB 33.38 million, with continued profitability in January–May 2026. Despite an asset-liability ratio above 96%, the market approach — selected over the asset-based approach — appraised the 51% stake at about RMB 178.4 million, broadly matching the listing price.

SENVIV is building a digital twin foundation from 12 million hours of physiological time-series data. While current health AI can interpret text and provide recommendations, it lacks direct access to human physiological data, making the “biological human” the next frontier for AI. Continuous vital sign data is fundamentally different from internet-derived data: difficult to observe, collect, and structure, it is often described as “life’s dark matter.” SENVIV uses a non-contact, minimally intrusive sensing approach, combining smart rings during the day with non-contact devices at night to reduce device burden and support long-term adherence. After 12 years of continuous data collection, the company has accumulated a large-scale vital sign dataset, including 12 million hours of continuous physiological data, of which 3.6 million hours were collected in clinical settings.

In H1 2026, Neutech Group's elderly care technology and services business grew revenue 57.4% year over year, the group's fastest-growing segment — marking the shift of its smart elderly care services from Shenyang pilot exploration to nationwide scaled replication. China's 320 million-plus elderly population faces fragmented services, difficult supply-demand matching, and regulatory gaps, and traditional single-point systems have left information silos. As AI and big data mature and policy promotes the "15-minute eldercare service circle", a city-level "digital foundation" for elderly care spanning institutions, communities, and home-based care has become a key industry entry point. Neutech launched the "Shengqing Kangyang" platform in Shenyang in 2025; with a year of smooth operations, it provides a replicable digital solution to the silver-aging challenge, ushering the industry into a new cycle of high-quality development.

China’s innovative drug BD market is heating up in 2026, with the industry shifting from “valuation-driven” to “performance- and global commercialization-driven.” VCBeat launched the “Year of Realization: Dialogues on BD” interview series to explore the practices of pharmaceutical BD decision-makers. Xie Xin, Executive Director of Sino Biopharm, has participated in multiple landmark transactions, overseeing M&A and financing activities. In recent years, Sino Biopharm has made significant progress in BD, completing four out-licensing deals with MNCs, including high-value collaborations with Sanofi and AstraZeneca in 2026. On the acquisition side, it acquired LaNova Medicines in 2025 and Hygieia in early 2026. In the interview, Xie Xin addressed the “selling young crops” debate, emphasizing that in-house R&D capabilities remain the top priority for corporate BD, while BD itself is a discipline built on timing, judgment, and persistence.

In H1 2026, Xunfei Healthcare, the first listed medical LLM company, achieved counter-trend growth: revenue reached RMB 446 million (up 49.4% YoY), gross profit growth outpaced revenue, and the net loss narrowed 20% — signaling a profit inflection point. Across its three segments (AI Diagnosis & Treatment Assistant, AI Health Assistant, AI Digital Foundation), AI Diagnosis & Treatment Assistant revenue hit RMB 202 million, pivoting from government-end primary care to hospital-end demand and opening a second growth curve; AI Health Assistant revenue surged 74.9% to RMB 182 million, becoming the core growth engine, potentially unlocking a RMB 10-billion consumer market; and AI Digital Foundation's gross margin jumped to 48.6%, improving earnings quality and confirming high-value medical AI's pricing power and the company's successful transformation into a high-quality medical AI platform company.

In May 2026, Roche Diagnostics acquired U.S. pathology AI company PathAI for RMB 7 billion, highlighting the valuation gap between Chinese and overseas pathology AI firms. Leading Chinese companies are typically valued at RMB 1–3 billion, several times below PathAI. Technologically, Chinese firms are broadly comparable and may even have advantages in areas such as training data scale. The key gap lies in business model maturity. PathAI has built a scalable commercial model, with over 60% of revenue from pharmaceutical companies, supporting greater business certainty and a valuation premium. In China, pathology AI commercialization remains exploratory, with limited historical basis for charging. Although policies introduced in late 2025 established a framework, many regions still lack independent billing codes for pathology AI. Meanwhile, national policies are increasingly promoting dedicated fee structures.

China's Center for Drug Evaluation (CDE) has signaled that YL202, an injectable HER3-targeted antibody-drug conjugate (ADC) developed by MediLink Therapeutics, is being considered for Breakthrough Therapy Designation for the treatment of previously treated, unresectable locally advanced, recurrent or metastatic melanoma. If approved, YL202 would become the first HER3 ADC to receive breakthrough therapy status in China. Currently in Phase III clinical development, YL202 is built on MediLink's proprietary TMALIN platform. The potential designation underscores the significant unmet medical need in advanced melanoma and highlights the growing competitiveness of Chinese biotech in the rapidly expanding ADC space, where no HER3 ADC has been approved globally to date. MediLink has also secured a major licensing deal with BioNTech worth up to $1 billion, reflecting strong global interest in Chinese-developed oncology therapies.

Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH), has obtained approval from China's National Medical Products Administration (NMPA) to manufacture ruxolitinib phosphate tablets under three drug registration certificates. The approved indications cover the treatment of myelofibrosis and graft-versus-host disease (GVHD), expanding treatment options for Chinese patients with rare blood disorders. Ruxolitinib, originally co-developed by Incyte Corporation and Novartis AG, was first approved by the U.S. FDA in 2011. This domestic production approval marks a significant milestone for SPH, strengthening its portfolio of specialized therapies for rare diseases and improving patient access to effective treatments for complex hematologic conditions.

On August 28, 2026, DualityBio entered a global collaboration with Genentech, a Roche Group company, to develop next-generation ADCs using its DUPAC™ platform. DualityBio received $45 million upfront and is eligible for over $1 billion in milestone payments. DualityBio will lead discovery and early clinical development, while Genentech will hold exclusive global licensing rights and oversee later development and commercialization. The deal highlights the rising global competitiveness of Chinese ADC innovation. As ADC technology enters a new phase of iteration, tumor resistance remains a key challenge. DUPAC™ is DualityBio’s next-generation payload platform designed to address such limitations, with ADCs based on DUP5 and DUP9 showing robust preclinical results.

In mid-June, Novo Nordisk’s global management visited China to integrate Chinese R&D expertise into its global strategy. China is emerging as a global innovation “accelerator,” combining scientific strength with cost efficiency. Novo Nordisk is expanding collaboration from early research to preclinical candidate development, incorporating Chinese innovations into its global pipeline. From January to June 2026, China’s outbound innovative-drug licensing deals hit a record high, with Chinese pharma companies accounting for eight of the top 10 global deals. MNC transactions by Eli Lilly and AstraZeneca focused on early-stage assets. McKinsey data show China’s biopharma discovery and development timelines are shorter than the global average, highlighting a structural efficiency advantage. China now accounts for about 30% of global drug candidates in development, while clinical trials surpassed 5,000.

InnoCare Pharma secured CDE approval to launch a registrational Phase III trial of its BCL-2 inhibitor mesutoclax in AML, setting up a head-to-head challenge against AbbVie’s venetoclax. China’s health insurance instant settlement now covers over 90% of designated medical institutions, while the new DRG/DIP 3.0 payment scheme promotes “same disease, same payment” at grassroots facilities. Biokin’s BL-B01D1 met its primary endpoint in a Phase III lung cancer trial, Harbour BioMed’s HBM7004 received IND approval in China, and AstraZeneca launched tezepelumab for severe asthma. EyePoint’s faricimab implant failed its Phase III trial, triggering a sharp drop in Betta Pharmaceuticals’ shares. Meanwhile, Enhertu demonstrated superior first-line efficacy in lung cancer, Chugai licensed a dengue antibody to GSK, Macau announced free community healthcare under its new Five-Year Plan, and YimuFeng filed for a Hong Kong IPO to advance its solid tumor CAR-T therapy.

Over the past three years, multinational pharmaceutical companies (MNCs) have repositioned China from a sales market to a global pharmaceutical innovation hub, elevating China-based business development (BD) teams in strategic decision-making. In the past two years, MNCs have strengthened local BD capabilities by delegating asset transaction authority, restructuring organizations, expanding teams, and optimizing collaboration systems. Two major approaches have emerged: the vertical direct-connection model, which removes reporting layers and improves local project decision efficiency, as seen in Sanofi, Merck, and Boehringer Ingelheim; and the China Hub upgrade model, which positions China as an Asia-Pacific or global innovation center, elevates BD functions, and increases focus on early-stage pipelines.

Just 60 days after the approval of Vanflyta® (quizartinib tablets) in China for FLT3-ITD-positive acute myeloid leukemia, Daiichi Sankyo has entered into an exclusive promotion agreement with Innovent Biologics for the mainland China market. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent assumes full commercialization and promotional duties. This collaboration reflects a broader strategic recalibration among multinational pharmaceutical companies, who are increasingly leveraging local partners’ commercial infrastructure to navigate China’s evolving and highly competitive innovative drug landscape. The move underscores a shift from traditional self-operated models toward ecosystem integration, highlighting the rising value of Chinese biopharma firms as essential enablers of global innovation commercialization.

AstraZeneca and CSPC Pharmaceutical Group have signed a joint venture agreement to construct a next-generation biologics drug substance manufacturing facility in Shijiazhuang, China. CSPC holds 51% and AstraZeneca 49% of the JV, which will initially focus on global supply of agreed biologics drug substances, with potential expansion based on capacity and demand. This strategic move reflects a shift in multinational pharma’s China strategy—from market access and product licensing to co-building global innovation and supply capabilities—leveraging CSPC’s AI-driven cGMP manufacturing infrastructure and AstraZeneca’s global quality and supply chain expertise.

Danaher Corporation officially opened its upgraded Leica Shanghai R&D and Manufacturing Base in Pudong on July 16, 2026, alongside the launch of its enhanced “Launching China 3.0” local strategy. The upgraded facility, now part of Danaher’s six regional innovation centers and designated as the Danaher China Lean Excellence Center, integrates R&D, manufacturing and lean operations to better serve customers in China while bringing China-developed solutions into the company’s global innovation network. Gustavo Perez-Fernandez, Danaher Diagnostics’ executive president, cited Shanghai’s healthcare ecosystem and talent pool as core advantages. Now a top global Leica hub, the base runs 19 pathology and 13 microscopy production lines.

Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.